A new case report has shed light on the challenges and promise of treating difficult-to-treat depression (DTD), a condition often mistaken for treatment-resistant depression (TRD) but with far more complex roots. Unlike TRD, which is defined by a lack of response to at least two antidepressant medications, DTD reflects a broader spectrum of clinical and psychological obstacles that prevent recovery, including unresolved trauma, psychiatric comorbidities, and poor treatment adherence. The findings were published in the journal Case Reports in Psychiatry.
The case follows a 63-year-old woman with a long history of depression, unresolved grief, and failed pharmacological attempts. Her condition worsened significantly after the death of her mother during the Covid pandemic, triggering intense guilt and sorrow. Despite trying various medications, including SSRIs, SNRIs, mood stabilisers, and benzodiazepines, the patient failed to achieve lasting remission. She also struggled with significant side effects, particularly weight gain, which led to repeated treatment discontinuation.
This case illustrates the pivotal role of personal history in managing DTD. The patient’s background included childhood trauma, a rigid upbringing influenced by a neurological condition, and a complex family dynamic in which she assumed a caretaker role. These psychological burdens interfered with her ability to process grief and engage in consistent treatment.
Walter Paganin, PhD, from the University of Rome, noted: “DTD is not merely a pharmacological label but a descriptive clinical construct useful for identifying patients whose illness trajectory is prolonged, complex, and functionally impairing, despite appropriate treatment.”
Rather than focusing solely on medication, clinicians adopted a fully integrated and personalised strategy. A multidisciplinary care team developed a plan that involved trauma-informed psychotherapy, pharmacological adjustments, and psychoeducation. Family members, particularly the patient’s husband, were brought into the therapeutic process to address hidden relational tensions and improve communication. This family-centred approach proved essential in reducing the patient’s emotional burden and increasing her commitment to treatment.
Over the course of two years, the patient participated in psychotherapy sessions that explored her past trauma and grief while receiving careful medication adjustments based on continuous clinical assessments. She also engaged in resocialisation activities, including gym membership and a theatre course, which helped restore her self-esteem and social functioning.
Paganin underscored the importance of recognising DTD early to improve outcomes. “The idea that patients must ‘fail’ two antidepressants before qualifying for more intensive care is reductive and often counterproductive,” he said. “Early identification of DTD in this case allowed us to avoid redundant pharmacological trials and capitalise on non-pharmacological resources.”
Clinicians used structured diagnostic tools such as the Hamilton Rating Scale for Depression (HRS-D), the Global Assessment of Functioning (GAF), and the Difficult-to-Treat Depression Questionnaire (DTDQ) to track progress. Her HRS-D score dropped from 26 to 10, GAF rose from 40 to 75, and her DTDQ score decreased from 90 to 44, indicating substantial recovery.
Although neurostimulation therapies were discussed, the patient declined them, preferring to focus on therapeutic and social pathways. The results demonstrate that in cases of DTD, the goal is not simply symptom elimination but long-term stability and improved quality of life. This requires clinicians to look beyond conventional definitions of resistance and to craft highly personalised interventions that address the full psychosocial context of the disorder.
Paganin further emphasised the conceptual importance of this treatment model. “Personalised medicine in psychiatry extends beyond genetics or biomarkers. It means tailoring treatment plans to the patient’s clinical history, cognitive profile, expectations, and contextual resources.” He added: “This case supports the value of an integrated, team-centred approach aimed at restoring the patient’s life trajectory rather than simply reducing symptoms.”
